Ikarian Capital’s 2seventy bio TSVT Stock Holding History

Ikarian Capital’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-99	Closed	-$1K	–	202
2022 Q1	$1K	Buy	99 +6	+6%	+$102	﹤0.01%	196
2021 Q4	$2K	Buy	+93	New	+$2.9K	﹤0.01%	186

Other funds holding TSVT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ikarian Capital's TSVT Position: Q2 2022 in Review

Ikarian Capital sold out of 2seventy bio (TSVT) in Q2 2022, closing a stake of 99 shares — an estimated $1K sold.

Ikarian Capital first reported a position in TSVT in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 132 funds tracked by Wall St. Rank hold TSVT as of Q2 2022.

Ikarian Capital reported no remaining 2seventy bio position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 99 2seventy bio shares in Q2 2022, an estimated $1K.
Ikarian Capital first reported a position in 2seventy bio in Q4 2021 and held it in 2 quarters.
Ikarian Capital's 2seventy bio position peaked at $2K in Q4 2021.
132 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.